← brief for 2026-09-06 · Slowing decline

Continuation of sodium-glucose co-transporter 2 inhibitors in advanced chronic kidney disease: a retrospective study with inverse probability of treatment weighting analysis.

Key takeaways

SGLT2 inhibitors are diabetes drugs that also slow kidney disease, but doctors often stop them once the kidney filtering rate (eGFR) falls to 20 or below, because there is little evidence for that stage. This study looked back at 1,011 people who had taken the drug for at least 3 months and reached that level between 2015 and 2021. 585 kept taking it and 426 stopped. Patients were not randomly assigned, so this shows a link between staying on the drug and later kidney outcomes, not proof of cause.

Who did this work

Ng JK · Chow EY · Fung WW · Chan GC · Chow KM · Szeto CC

Source

Article · PubMed, CKD severity and reversal · 2026 Aug 7
https://pubmed.ncbi.nlm.nih.gov/42699509/